Health-related quality of life in patients with psoriasis: a systematic review of the European literature

Abstract

HRQoL has been broadly addressed in patients with psoriasis in Europe. Several disease- and patient-related factors contributed to its deterioration. Therapeutic measures with proven effectiveness in controlling disease symptoms and reducing PASI should be considered in patients with a severe disease who have a poorer HRQoL.

A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: potential biases in treatment decisions

“…Over the past two decades, it has pervaded the management of psoriasis patients in multiple ways. It serves as an easy‐to‐use instrument and a useful benchmark to evaluate treatment efficacy both in routine clinical work and in a variety of researches . It is by far the most commonly applied HRQoL tool in randomized controlled trials for interventions in psoriasis .…”

“…It serves as an easy-to-use instrument and a useful benchmark to evaluate treatment efficacy both in routine clinical work and in a variety of researches. 4 It is by far the most commonly applied HRQoL tool in randomized controlled trials for interventions in psoriasis. 5 According to the European consensus, DLQI is among the diagnostic criteria of moderate-to-severe psoriasis to determine which patients need to be offered systemic treatments.…”

Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE

“…Psoriasis is a chronic, immune‐mediated skin disorder affecting 1·2–8·5% of the European population . The disease is associated with reduction of the patient's quality of life (QoL), and moderate‐to‐severe cases may incur high costs relating to hospitalizations and treatments as well as productivity losses . Systemic treatment with biologics provides an effective treatment option for moderate‐to‐severe cases of psoriasis .…”

The impact of psoriasis on professional life: PsoPRO, a French national survey

“…Despite this indisputable progress, the disease remains disabling in many patients, due to its high physical, mental and social burden . Quality of life has been extensively investigated, and numerous studies have revealed a negative impact of the disease on this parameter . The professional activity of patients with psoriasis, assessed from their professional status or work productivity and activity impairment, has already been studied in several surveys, but in the absence of a control group, the specific consequences of the disease could not be measured .…”

“…7 Quality of life has been extensively investigated, and numerous studies have revealed a negative impact of the disease on this parameter. 8 The professional activity of patients with psoriasis, assessed from their professional status or work productivity and activity impairment, has already been studied in several surveys, but in the absence of a control group, the specific consequences of the disease could not be measured. 6,[9][10][11][12][13][14][15][16][17][18][19] Moreover, these studies did not usually take account of the subgroup of patients with psoriatic arthritis.…”